

Key Document Supporting Information

TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH BIOLOGICS (PATIENTS OVER 15 YEARS OF AGE)

Key Document code:	Treatment of Inflammatory Bowel Disease with Biologics (In patients over 15 years of age)	
Key Document Owner:	<i>Helen Osinski</i>	<i>Senior IBD CNS</i>
Approved by:	<i>Medicines Safety committee</i>	
Date of Approval:	<i>04/11/2019</i>	
This is the most upto date and should be used until a revised version is in place:	<i>04/11/2021</i>	

AMENDMENTS MADE TO KEY DOCUMENT

[Key Amendments](#)

CONSULTATION

This Treatment pathway has been circulated to the following individuals for consultation

Name	Designation
Ian Gee, Amul Elagib, Nick Hudson, Thea Haldane, Danny Cheung	Gastroenterology consultants
Louise Williams	Specialist pharmacist - gastroenterology

This Treatment pathway has been circulated to the chair(s) of the following committee's / groups;

Gastroenterology governance meeting – 26/10/2018 - approved

Medicines Safety Committee – 4th November 2019

IMPLEMENTATION

Plan for implementation

I will email all relevant staff within the gastroenterology directorate, Aconbury 4 also childrens clinic, medical daycase and AEC at the Alexandra hospital where these drugs are used and administered.

DISSEMINATION

As above

Key Document Supporting Information

MONITORING AND COMPLIANCE				
<p>This section should identify how the Trusts plan to monitor compliance with and the effectiveness of this Treatment pathway. It should include auditable standards and/or key performance indicators (KPIs) and details on the methods for monitoring compliance</p>				
What	How	Who	Where	When
<i>These are the 'key' parts of the process that we are relying on to manage risk.</i>	<i>What are we going to do to make sure the key parts of the process we have identified are being followed?</i>	<i>Who is responsible for the check?</i>	<i>Who will receive the monitoring results?</i>	<i>Set achievable frequencies.</i>

Key Document Supporting Information

SUPPORTING DOCUMENT ONE – EQUALITY IMPACT ASSESSMENT TOOL

To be completed by the Treatment pathway owner and submitted to the appropriate committee for consideration and approval.

		Yes/No
1.	Does the treatment pathway affect one group less or more favourably than another on the basis of:	
	Race	No
	Ethnic origins (including gypsies and travellers)	No
	Nationality	No
	Gender	No
	Disability	No
	Religion or belief	No
	Sexual Orientation	No
	Age	No
2.	Is there any evidence that some groups are affected differently?	No
3.	If you have identified potential discrimination, are any exceptions valid, legal and/or justifiable?	Na
4.	Is the impact of the policy/guidance likely to be negative? If so can the impact be avoided?	No
5.	What alternatives are there to achieving the policy/guidance without the impact?	Na
6.	Can we reduce the impact by taking different action?	Na
7.	Other comments	

If you have identified a potential discriminatory impact of this key document, please refer it to Human Resources, together with any suggestions as to the action required to avoid/reduce this impact.

For advice in respect of answering the above questions, please contact Human Resources.

Key Document Supporting Information

SUPPORTING DOCUMENT TWO – FINANCIAL IMPACT ASSESSMENT

To be completed by the Treatment pathway owner and submitted to the appropriate committee for consideration and approval.

		Yes/No
1.	Does the implementation of this document require any additional Capital resources	No
2.	Does the implementation of this document require additional revenue	No
3.	Does the implementation of this document require additional manpower	No
4.	Does the implementation of this document release any manpower costs through a change in practice	no
5.	Are there additional staff training costs associated with implementing this document which cannot be delivered through current training programmes or allocated training times for staff	no
6.	Other comments	

If the response to any of the above is yes, please complete a business case and which is signed by your Finance Manager and Directorate Manager for consideration by the Accountable Director before progressing to the relevant committee for approval